Vis enkel innførsel

dc.contributor.authorHøivik, Erling Andre
dc.contributor.authorHodneland, Erlend
dc.contributor.authorDybvik, Julie Andrea
dc.contributor.authorWagner-Larsen, Kari Strøno
dc.contributor.authorFasmer, Kristine Eldevik
dc.contributor.authorBerg, Hege Fredriksen
dc.contributor.authorHalle, Mari Kyllesø
dc.contributor.authorHaldorsen, Ingfrid S.
dc.contributor.authorKrakstad, Camilla
dc.date.accessioned2021-12-15T13:17:40Z
dc.date.available2021-12-15T13:17:40Z
dc.date.created2021-12-10T20:55:01Z
dc.date.issued2021
dc.identifier.issn2399-3642
dc.identifier.urihttps://hdl.handle.net/11250/2834480
dc.description.abstractPrognostication is critical for accurate diagnosis and tailored treatment in endometrial cancer (EC). We employed radiogenomics to integrate preoperative magnetic resonance imaging (MRI, n = 487 patients) with histologic-, transcriptomic- and molecular biomarkers (n = 550 patients) aiming to identify aggressive tumor features in a study including 866 EC patients. Whole-volume tumor radiomic profiling from manually (radiologists) segmented tumors (n = 138 patients) yielded clusters identifying patients with high-risk histological features and poor survival. Radiomic profiling by a fully automated machine learning (ML)-based tumor segmentation algorithm (n = 336 patients) reproduced the same radiomic prognostic groups. From these radiomic risk-groups, an 11-gene high-risk signature was defined, and its prognostic role was reproduced in orthologous validation cohorts (n = 554 patients) and aligned with The Cancer Genome Atlas (TCGA) molecular class with poor survival (copy-number-high/p53-altered). We conclude that MRI-based integrated radiogenomics profiling provides refined tumor characterization that may aid in prognostication and guide future treatment strategies in EC.en_US
dc.language.isoengen_US
dc.publisherNatureen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleA radiogenomics application for prognostic profiling of endometrial canceren_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.source.articlenumber1363en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doihttps://doi.org/10.1038/s42003-021-02894-5
dc.identifier.cristin1967289
dc.source.journalCommunications Biologyen_US
dc.identifier.citationCommunications Biology. 2021, 4, 1363.en_US
dc.source.volume4en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal